Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 60Breast Neoplasms 54Ovarian Neoplasms 35Triple Negative Breast Neoplasms 28Lung Neoplasms 25Fallopian Tube Neoplasms 24Endometrial Neoplasms 24Neoplasm Metastasis 22Squamous Cell Carcinoma of Head and Neck 19Parkinson Disease 4, Autosomal Dominant Lewy Body 19Neoplasms 15Esophageal Neoplasms 13Esophageal Squamous Cell Carcinoma 12Carcinoma, Ovarian Epithelial 10Stomach Neoplasms 9Head and Neck Neoplasms 9Carcinoma 9Colorectal Neoplasms 8Adenocarcinoma Of Esophagus 7Adenocarcinoma 7Peritoneal Neoplasms 6Uterine Cervical Neoplasms 5Melanoma 5Small Cell Lung Carcinoma 4Oropharyngeal Neoplasms 4Cholangiocarcinoma 4Carcinoma, Transitional Cell 4Urinary Bladder Neoplasms 3Respiratory Tract Neoplasms 3Recurrence 3

Interventions

cemiplimab 1Taxes 1Surgical Procedures, Operative 1Specimen Handling 1Radiotherapy 1Radiation 1Platinum 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Cisplatin 1Chemoradiotherapy 1Carboplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sinonasal Squamous Cell Carcinoma × Paclitaxel × 90 days × Clear all
NCT07281417 2026-05-22

Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma

National Cancer Institute (NCI)

Phase 2 Recruiting
108 enrolled

Sinonasal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡